PVLA (Pieris Pharma) Net Profit

PVLA (Pieris Pharmaceuticals, Inc.) - company brandmark

Pieris Pharmaceuticals (PVLA) possesses a unique technology for creating compact anticalin proteins, which penetrate tissues more effectively than antibodies to combat cancer. The company develops advanced treatments for oncology and respiratory diseases, generating revenue through licensing agreements with partners. This daily price chart reflects a separate profit level of -0.06. As management is currently updating clinical targets, the market is cautiously awaiting concrete restructuring successes.

PVLA (Pieris Pharmaceuticals) Net Profit history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Pieris Pharmaceuticals, Inc. (PVLA)

- price and consensus price forecast:
Stock Quotes Pieris Corp|PVLA - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Pieris Corp|PVLA - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Pieris Pharmaceuticals|PVLA - Book Capitalization|Market Capitalization to Book Value pieris.com|PVLA - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Pieris Pharmaceuticals|PVLA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Pieris Pharma|PVLA - Company Total Debt|Debts to Book Capitalization Pieris Corp|PVLA - Company Long-Term Debt|Company Short-Term Indebtedness Pieris Pharmaceuticals|Immediate Liquidity pieris.com
- net income and valuation multiples indicators:
PVLA - Company Net Income
Summary company analysis:Pieris Pharmaceuticals
Core merchandise of Pieris Pharmaceuticals Inc

For Pieris Pharmaceuticals (PVLA), which develops anti-calin proteins, the company's reported profit visualizes the effectiveness of monetizing its scientific research. This indicator measures the daily rate of revenue generation, neutralizing the time gaps inherent in quarterly reporting. The metric captures the business's ability to adapt pricing to cost inflation. This price action reflects the financial stability of partnerships with pharma behemoths. A stable trend confirms the issuer's solvency within the current macro cycle.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN - Company Net Income|Profit After Tax PHAR|NKTR: Net Profit|UPB - Net Financial Result|ZBIO (Zenas Biopharma) - Net Profit|Company Net Income Immunome Inc IMNM|Company Net Income Gossamer Corp (GOSS)|KALV (KalVista Corp) - Final Profit|Net Profit SEPN (Septerna Inc)|Net Financial Result savarapharma.com (SVRA)|RIGL - Company Net Income|Net Financial Result AnaptysBio Inc ANAB|ATXS (Astria Pharma) - Net Income|enGene Corp - Final Profit|Company Net Income RAPT Therapeutics, Inc.|Aerovate - Profit After Tax|Net Profit ACRS|KYTX (Kyverna Therapeutics Inc.) - Final Profit|Net Profit TLSA (Tiziana Life Sciences PLC)|Net Profit Cabaletta Bio Inc CABA|VTYX - Company Net Income|Final Profit THTX (theratech.com)|Avalo Therapeutics (AVTX) - Company Net Income|Net Income Eledon Pharmaceuticals Inc.|AGEN (Agenus Inc) - Net Profit|Net Profit Climb Bio, Inc|Net Profit ZURA|Net Income atyrpharma.com ATYR|Net Profit ADAG (Adagene Inc.)|ImageneBio (IMA) - Company Net Income|STTK: Net Income|EQ - Net Profit|CNTB (connectbiopharm.com) - Net Income|IMUX: Profit After Payment of Taxes|ATRA (Atara Biotherapeutics, Inc.) - Net Profit|InflaRx GmbH (IFRX) - Net Financial Result|Net Profit XFOR|Net Income adicetbio.com ACET|Net Profit CELU (Celularity)|Net Profit inmunebio.com INMB|BRNS - Company Net Income|KZR: Company Net Income|SAB Biotherapeutics, Inc (SABS) - Company Net Income|AKTX - Net Financial Result|Company Net Income Enlivex Therapeutics Ltd|Q32 Bio Corp - Profit After Tax|Net Income GOVX (GeoVax)|Company Net Income EDSA (Edesa Biotech Inc)|Company Net Income iBio Corp IBIO|Carisma Therapeutics Inc - Company Net Income|XTL Biopharmaceuticals - Net Profit|BOLT - Net Profit|hcwbiologics.com (HCWB) - Company Net Income|Profit After Tax APVO (Aptevo Therapeutics Inc.)|AIM (AIM ImmunoTech) - Net Profit|ADTX: Final Profit|Net Profit GRI|Net Profit xortx.com (XRTX)|Company Net Income Vyome Holdings HIND|Final Profit REVB|INDP - Company Net Income|BiondVax Pharmaceuticals (SCNI) - Net Income|CALI: Net Profit|Affimed N.V. (AFMD) - Net Profit|Net Income ALLK|HOOK: Final Profit|Net Profit IGMS|Net Financial Result iTeos Pharma|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP - Net Income|THRD - Company Net Income